Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jo Shorthouse

Interim Editor of In Vivo

London, UK

Jo Shorthouse is the Interim Editor of In Vivo. She has contributed to various Pharma Intelligence publications, starting with Scrip in 2008. She has previously edited Scrip Good Clinical Practice, Scrip Clinical Research and the Scrip 100, been a managing editor on Pharma Intelligence’s Commercial team, and most recently turned her hand to freelance health care journalism and editorial consultancy. Jo has a wide-ranging knowledge of many aspects of the pharmaceutical industry which allows her to bring insights to the Pharma Intelligence and In Vivo teams.

Latest From Jo Shorthouse

Citeline And Norstella Merge To Provide End-To-End Solutions For Pharma

Publisher’s Spotlight: Citeline, the publisher of In Vivo, is to merge with fellow pharmaceutical solutions provider Norstella.

BioPharmaceutical Medical Device

Funding The Future: Accelerating The Long Walk To Innovation

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.

New Science StartUps and SMEs

Partnerships Picks For GeNeuro’s MS Antibody

The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.

New Science Research & Development

Muvon Therapeutics: The Road To Expansion

Deana Mohr, Muvon Therapeutics’ co-founder and chief executive, and one of In Vivo’s 2022 Rising Leaders, aspires to push the organization to the next level by scaling up the company and developing its therapies into marketable products.

Leadership Regenerative Medicine

Turning The Dial Up On Digital

The maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.

BioPharmaceutical Digital Health

A New Generation Invents Pharma’s Mirrored Future

Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.

Outlook 2022 Artificial Intelligence
See All
UsernamePublicRestriction

Register